Through this management of GLP-1 use, Excellus BCBS has realized cost savings, as indicated by the graph below: Excellus BCBS is using what appears to be the most sensible weight loss GLP-1 prior authorization criteria in the marketplace, without significantly disrupting rebates. -USI Partner What we know about the future of GLP-1 drugs In 2024, there were significant advancements with GLP-1 indications
Here are some other factors that will influence the extent of your results: Your activity levels and the type of activity you participate in Your weight at the beginning of your treatment plan Your resting metabolic rate Your diet In general, patients with much higher BMIs (class II and class III obesity) may begin to shed pounds within just the first couple of weeks
A dedicated cardiovascular outcomes trial (SURPASS-CVOT) comparing tirzepatide to dulaglutide is ongoing, with results not yet published
Can heartburn on tirzepatide damage my esophagus
No Known Drug Interactions Currently, there are no known direct, negative interactions (contraindications) between semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) and common over-the-counter laxatives
Direct weight-management head-to-head data remains limited, and individual response varies widely